Advertisement

Topics

Poly [ADP Ribose] Polymerase 2 ADP Ribosyltransferase Diphtheria Toxin Like 2 or NAD+ ADP Ribosyltransferase 2 or Poly[ADP Ribose] Synthase 2 or PARP2 or EC 2.4.2.30 Pipeline Review, H2 2017 [Report Updated: 31102017] Prices from USD $3500

16:06 EST 8 Nov 2017 | BioPortfolio Report Blog

Poly [ADP Ribose] Polymerase 2 ADP Ribosyltransferase Diphtheria Toxin Like 2 or NAD+ ADP Ribosyltransferase 2 or Poly[ADP Ribose] Synthase 2 or PARP2 or EC 2.4.2.30 Pipeline Review, H2 2017


Summary


Poly [ADP Ribose] Polymerase 2 ADP Ribosyltransferase Diphtheria Toxin Like 2 or NAD+ ADP Ribosyltransferase 2 or Poly[ADP Ribose] Synthase 2 or PARP2 or EC 2.4.2.30 pipeline Target constitutes close to 19 molecules. Out of which approximately 17 molecules are developed by companies and remaining by the universities/institutes. The latest report Poly [ADP Ribose] Polymerase 2 Pipeline Review, H2 2017, outlays comprehensive information on the Poly [ADP Ribose] Polymerase 2 ADP Ribosyltransferase Diphtheria Toxin Like 2 or NAD+ ADP Ribosyltransferase 2 or Poly[ADP Ribose] Synthase 2 or PARP2 or EC 2.4.2.30 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action MoA, route of administration RoA and molecule type.


Poly [ADP Ribose] Polymerase 2 ADP Ribosyltransferase Diphtheria Toxin Like 2 or NAD+ ADP Ribosyltransferase 2 or Poly[ADP Ribose] Synthase 2 or PARP2 or EC 2.4.2.30 Poly [ADPribose] polymerase 2 is an enzyme encoded by the PARP2 gene. It is involved in the base excision repair BER pathway, by catalyzing the poly ADPribosylation of a limited number of acceptor proteins involved in chromatin architecture and in DNA metabolism. This modification follows DNA damages and appears as an obligatory step in signaling pathway leading to the reparation of DNA strand breaks. The molecules developed by companies in PreRegistration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 1, 4, 7, 1 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Oncology which include indications Breast Cancer, Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cancer, Solid Tumor, Metastatic Breast Cancer, SmallCell Lung Cancer, Epithelial Ovarian Cancer, Gastric Cancer, Metastatic Hormone Refractory Castration Resistant, AndrogenIndependent Prostate Cancer, Diffuse Large BCell Lymphoma, Bile Duct Cancer Cholangiocarcinoma, Glioblastoma Multiforme GBM, Malignant Mesothelioma, Mantle Cell Lymphoma, Metastatic Pancreatic Cancer, NonHodgkin Lymphoma, NonSmall Cell Lung Cancer, Acute Myelocytic Leukemia AML, Acute Myeloblastic Leukemia, Adenocarcinoma Of The Gastroesophageal Junction, BCell Chronic Lymphocytic Leukemia, Chronic Myelocytic Leukemia CML, Chronic Myeloid Leukemia, Endometrial Cancer, Esophageal Cancer, Essential Thrombocythemia, Ewing Sarcoma, Follicular Lymphoma, Germ Cell Tumors, Germinomatous Seminomatous Germ Cell Tumors, Glioma, Head And Neck Cancer Squamous Cell Carcinoma, Hodgkin Lymphoma BCell Hodgkin Lymphoma, Laryngeal Cancer, Leiomyosarcoma, Lung Cancer, Marginal Zone Bcell Lymphoma, Melanoma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Colorectal Cancer, Metastatic Melanoma, Metastatic Ovarian Cancer, Metastatic Prostate Cancer, Myelofibrosis, Neuroblastoma, Neuroendocrine Tumors, Nongerminomatous Nonseminomatous Germ Cell Tumors, Oropharyngeal Cancer, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Peritoneal Tumor, Polycythemia Vera, Prostate Cancer, Rectal Cancer, Recurrent Glioblastoma Multiforme GBM, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Renal Cell Carcinoma, Soft Tissue Sarcoma, Squamous NonSmall Cell Lung Cancer, Testicular Cancer and Uveal Melanoma.


Furthermore, this report also reviews key players involved in Poly [ADP Ribose] Polymerase 2 ADP Ribosyltransferase Diphtheria Toxin Like 2 or NAD+ ADP Ribosyltransferase 2 or Poly[ADP Ribose] Synthase 2 or PARP2 or EC 2.4.2.30 targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industryspecific third party sources.


Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.


Scope


The report provides a snapshot of the global therapeutic landscape for Poly [ADP Ribose] Polymerase 2 ADP Ribosyltransferase Diphtheria Toxin Like 2 or NAD+ ADP Ribosyltransferase 2 or Poly[ADP Ribose] Synthase 2 or PARP2 or EC 2.4.2.30

The report reviews Poly [ADP Ribose] Polymerase 2 ADP Ribosyltransferase Diphtheria Toxin Like 2 or NAD+ ADP Ribosyltransferase 2 or Poly[ADP Ribose] Synthase 2 or PARP2 or EC 2.4.2.30 targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industryspecific sources

The report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, RD brief, licensing and collaboration details other developmental activities

The report reviews key players involved in Poly [ADP Ribose] Polymerase 2 ADP Ribosyltransferase Diphtheria Toxin Like 2 or NAD+ ADP Ribosyltransferase 2 or Poly[ADP Ribose] Synthase 2 or PARP2 or EC 2.4.2.30 targeted therapeutics and enlists all their major and minor projects

The report assesses Poly [ADP Ribose] Polymerase 2 ADP Ribosyltransferase Diphtheria Toxin Like 2 or NAD+ ADP Ribosyltransferase 2 or Poly[ADP Ribose] Synthase 2 or PARP2 or EC 2.4.2.30 targeted therapeutics based on mechanism of action MoA, route of administration RoA and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Poly [ADP Ribose] Polymerase 2 ADP Ribosyltransferase Diphtheria Toxin Like 2 or NAD+ ADP Ribosyltransferase 2 or Poly[ADP Ribose] Synthase 2 or PARP2 or EC 2.4.2.30 targeted therapeutics


Reasons to buy


Gain strategically significant competitor information, analysis, and insights to formulate effective RD strategies

Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Poly [ADP Ribose] Polymerase 2 ADP Ribosyltransferase Diphtheria Toxin Like 2 or NAD+ ADP Ribosyltransferase 2 or Poly[ADP Ribose] Synthase 2 or PARP2 or EC 2.4.2.30

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Poly [ADP Ribose] Polymerase 2 ADP Ribosyltransferase Diphtheria Toxin Like 2 or NAD+ ADP Ribosyltransferase 2 or Poly[ADP Ribose] Synthase 2 or PARP2 or EC 2.4.2.30 development landscape

Develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Original Article: Poly [ADP Ribose] Polymerase 2 ADP Ribosyltransferase Diphtheria Toxin Like 2 or NAD+ ADP Ribosyltransferase 2 or Poly[ADP Ribose] Synthase 2 or PARP2 or EC 2.4.2.30 Pipeline Review, H2 2017 [Report Updated: 31102017] Prices from USD $3500

NEXT ARTICLE

More From BioPortfolio on "Poly [ADP Ribose] Polymerase 2 ADP Ribosyltransferase Diphtheria Toxin Like 2 or NAD+ ADP Ribosyltransferase 2 or Poly[ADP Ribose] Synthase 2 or PARP2 or EC 2.4.2.30 Pipeline Review, H2 2017 [Report Updated: 31102017] Prices from USD $3500"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Polymerase Chain Reaction (PCR)
PCR (Polymerase Chain Reaction) uses the ability of DNA polymerase (enzymes that create DNA molecules by assembling nucleotides, the building blocks of DNA. These enzymes are essential to DNA replication and usually work in pairs to create two ident...

Enzymes
Enzymes are proteins that catalyze (i.e., increase the rates of) chemical reactions. In enzymatic reactions, the molecules at the beginning of the process, called substrates, are converted into different molecules, called products. Almost all chemical re...

Bioinformatics
Bioinformatics is the application of computer software and hardware to the management of biological data to create useful information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied...